FDA pilot offers generative AI medical devices a path to patients before they are authorized

The Food and Drug Administration has accepted four generative artificial intelligence medical devices into its new TEMPO pilot program, according to STAT News. The pilot permits digital health companies to bring certain AI-driven products to patients before those products receive full marketing authorization.

Among the accepted devices are AI products developed by Cadence and Limbic, per the report. STAT News did not detail the full list of participating companies or specify each device’s intended clinical function within this summary.

The TEMPO pathway represents a shift in how the agency handles generative AI tools in health care, allowing earlier patient access ahead of standard authorization review. STAT News frames the pilot as a mechanism that could reshape existing regulatory timelines for AI-based medical devices, though the publication notes this arrangement also raises questions about patient safety oversight during the period before formal authorization is granted.

The report does not specify the pilot’s total duration, the criteria used to select participating devices, or what data the FDA will require before granting full authorization to products released under TEMPO. STAT News’ account is limited to confirmation of the four accepted devices and the general structure of the pathway, attributing the analysis of its regulatory implications to its own reporting rather than to statements from the FDA or the companies involved.